Core Viewpoint - Kingsray reported a significant increase in revenue and adjusted net profit for the first half of 2025, showcasing strong resilience and improved profitability [2][3]. Financial Performance - The company achieved a revenue of $518.8 million, representing a year-on-year growth of 81.9% [2]. - Gross profit reached $320.6 million, with a year-on-year increase of 140.1% [2]. - Adjusted net profit from continuing operations surged to $178 million, marking a staggering increase of 509.6% [2]. - The net loss narrowed to $24.5 million, a substantial improvement from a loss of $215.6 million in the same period last year [2]. Business Segments - Revenue from life sciences services and products was $247.6 million, reflecting a growth of 11.3% [2]. - The biopharmaceutical CDMO business saw remarkable performance, with revenue reaching $246.9 million, a year-on-year increase of 511.1% [2]. - Revenue from industrial synthetic biology products was $28.3 million, up by 8.4% [2]. Profitability Analysis - Adjusted operating profit for the life sciences business was approximately $46.4 million [3]. - The adjusted operating profit for the burgeoning biological sector was $150 million [3]. - The company transitioned from "Made in China" to "Intelligent Manufacturing Globally," driven by innovation and internationalization [3].